Becton, Dickinson and Company company logo

# 1st Gen Model Becton, Dickinson and Company Surgical & medical instruments

76.79% successful of 56 deals
$218.77 Last close price
at 14-dec-2017


Model's trade recommendations 0.46% Return for period

8.33% Annual return

$49.91B Market Cap

β 1.07  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 0.46%
52wk return 6.91%
52wk Range
Sortino ratio 1.75
Sharpe ratio 1.23
Norm. RMSE 0.32%
Downside risk 4.49%
Volatility 6.38%
  • 3.00 (1.37%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Becton, Dickinson & Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Industry sector: Medical

Sector classification: Surgical & medical instruments

Deep Learning based analysis and prediction model for Becton, Dickinson and Company (BDX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BDX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 225M
P/E 23.07
Shares Outstanding 228M
% Held by Insiders 1.40%
% Held by Institutions 88.60%
EPS (last reported FY) $9.48
EPS (last reported Q) $2.40
EPS, estimated (last reported Q) $2.38
Total revenues $12 B
Net income $1 B